Research Paper Volume 15, Issue 20 pp 10996—11011

Figure 1. BTN2A2 expression in patients with cancer. (A) BTN2A2 expression in pan-cancer using TIMER. (B) BTN2A2 expression in pan-cancer using GEPIA 2. (C) BTN2A2 expression in pan-cancer using TCGA. Abbreviations: ACC: Adrenocortical carcinoma; BRCA: Bladder Urothelial carcinoma; CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma; DLBC: Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; LAML: Acute Myeloid Leukemia; LUSC: Lung squamous cell carcinoma; MESO: Mesothelioma; PAAD: Pancreatic adenocarcinoma; PCPG: Pheochromocytoma and Paraganglioma; READ: Rectum adenocarcinoma; SARC: Sarcoma; TGCT: Testicular Germ Cell Tumors; THYM: Thymoma; UCS: Uterine carcinosarcoma; UVM: Uveal Melanoma; BLCA: Bladder urothelial carcinoma; CHOL: Cholangiocarcinoma; COAD: Colon adenocarcinoma; ESCA: Esophageal carcinoma; HNSC: Head and neck squamous cell carcinoma; KICH: Kidney Chromophobe; KIRP: Kidney renal clear cell carcinoma; KIRC: Kidney renal clear cell carcinoma; LIHC: Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; PRAD: Prostate adenocarcinoma; SKCM: Skin Cutaneous Melanoma; STAD: Stomach adenocarcinoma; THCA: Thyroid carcinoma; UCEC: Uterine corpus endometrial carcinoma. ^*P < 0.05, ^**P < 0.01, ^***P < 0.001.